Cyclin D1 extent | |||||
Negative | 2 | (5%) | 39 | (97.5%) | < 0.001 |
Positive | 38 | (95%) | 1 | (2.5%) | |
DJ1 extent | |||||
Negative | 6 | (15%) | 39 | (97.5%) | < 0.001 |
Positive | 34 | (85%) | 1 | (2.5%) | |
Cyclin D1 extent /DJ1 extent | |||||
Negative/Negative | 2 | (5%) | 38 | (95%) | < 0.001 |
Negative/Positive | 0 | (0%) | 1 | (2.5%) | |
Positive/Negative | 4 | (10%) | 1 | (2.5%) | |
Positive/Positive | 34 | (85%) | 0 | (0%) | |
Cyclin D1 intensity | |||||
0 | 2 | (5%) | 39 | (97.5%) | < 0.001 |
1 | 5 | (12.5%) | 1 | (2.5%) | |
2 | 16 | (40%) | 0 | (0%) | |
3 | 17 | (42.5%) | 0 | (0%) | |
DJ1 intensity | |||||
0 | 6 | (15%) | 39 | (97.5%) | < 0.001 |
1 | 4 | (10%) | 0 | (0%) | |
2 | 14 | (35%) | 1 | (2.5%) | |
3 | 16 | (40%) | 0 | (0%) | |
Cyclin D1 intensity/DJ1 intensity | |||||
0/0 | 2 | (5%) | 38 | (95%) | < 0.001 |
0/1 | 0 | (0%) | 0 | (0%) | |
0/2 | 0 | (0%) | 1 | (2.5%) | |
1/0 | 1 | (2.5%) | 1 | (2.5%) | |
1/1 | 4 | (10%) | 0 | (0%) | |
1/2 | 0 | (0%) | 0 | (0%) | |
2/0 | 3 | (7.5%) | 0 | (0%) | |
2/1 | 0 | (0%) | 0 | (0%) | |
2/2 | 10 | (25%) | 0 | (0%) | |
2/3 | 3 | (7.5%) | 0 | (0%) | |
3/2 | 4 | (10%) | 0 | (0%) | |
3/3 | 13 | (32.5%) | 0 | (0%) | |
Cyclin D1 overexpression | |||||
Negative | 23 | (57.5%) | |||
Positive | 17 | (42.5%) | |||
DJ-1 overexpression | |||||
Negative | 21 | (52.5%) | |||
Positive | 19 | (47.5%) |
Gleason score | Relapse | ||||
< 7 | 7 | 17.5% | Absent | 16 | 40% |
= 7 | 11 | 27.5% | Present | 24 | 60% |
➢7 | 22 | 55% | |||
T | Distant metastasis | ||||
T1 | 5 | 12.5% | Absent | 16 | 40% |
T2 | 14 | 35% | Present | 24 | 60% |
T3 | 21 | 52.5% | |||
Stage | Hormone Refractory Relapse | (N=24) | |||
Stage I | 3 | 7.5% | Absent | 7 | 29.2% |
Stage IIa | 6 | 15% | Present | 17 | 70.8% |
Stage IIb | 10 | 25% | |||
Stage III | 21 | 25% |
Gleason score | |||||||
< 7 | 7 | (17.5%) | 7 | (100%) | 0 | (0%) | < 0.001 |
= 7 | 11 | (27.5%) | 9 | (81.8%) | 2 | (18.2%) | |
➢7 | 22 | (55%) | 0 | (0%) | 22 | (100%) | |
T | |||||||
T1 | 5 | (12.5%) | 5 | (100%) | 0 | (0%) | < 0.001 |
T2 | 14 | (35%) | 11 | (78.6%) | 3 | (21.4%) | |
T3 | 21 | (52.5%) | 0 | (0%) | 21 | (100%) | |
Stage | |||||||
Stage I | 3 | (7.5%) | 3 | (100%) | 0 | (0%) | < 0.001 |
Stage IIa | 6 | (15%) | 6 | (100%) | 0 | (0%) | |
Stage IIb | 10 | (25%) | 7 | (70%) | 3 | (30%) | |
Stage III | 21 | (25%) | 0 | (0%) | 21 | (100%) | |
Cyclin D1 extent | |||||||
Negative | 2 | (5%) | 2 | (100%) | 0 | (0%) | 0.154 |
Positive | 38 | (95%) | 14 | (36.8%) | 24 | (63.2%) | |
DJ1 extent | |||||||
Negative | 6 | (15%) | 6 | (100%) | 0 | (0%) | 0.002 |
Positive | 34 | (85%) | 10 | (29.4%) | 24 | (70.6%) | |
Cyclin D1 extent /DJ1 extent | |||||||
−ve/−ve | 2 | (5%) | 2 | (100%) | 0 | (0%) | 0.003 |
+ve/−ve | 4 | (10%) | 4 | (100%) | 0 | (0%) | |
+ve/+ve | 34 | (85%) | 10 | (29.4%) | 24 | (70.6%) | |
Cyclin D1 intensity | |||||||
0 | 2 | (5%) | 2 | (100%) | 0 | (0%) | 0.002 |
1 | 5 | (12.5%) | 5 | (100%) | 0 | (0%) | |
2 | 16 | (40%) | 5 | (31.3%) | 11 | (68.8%) | |
3 | 17 | (42.5%) | 4 | (23.5%) | 13 | (76.5%) | |
DJ1 intensity | |||||||
0 | 6 | (15%) | 6 | (100%) | 0 | (0%) | < 0.001 |
1 | 4 | (10%) | 4 | (100%) | 0 | (0%) | |
2 | 14 | (35%) | 6 | (42.9%) | 8 | (57.1%) | |
3 | 16 | (40%) | 0 | (0%) | 16 | (100%) | |
Cyclin D1 intensity/DJ1 intensity | |||||||
0/0 | 2 | (5%) | 2 | (100%) | 0 | (0%) | < 0.001 |
1/0 | 1 | (2.5%) | 1 | (100%) | 0 | (0%) | |
1/1 | 4 | (10%) | 4 | (100%) | 0 | (0%) | |
2/0 | 3 | (7.5%) | 3 | (100%) | 0 | (0%) | |
2/2 | 10 | (25%) | 2 | (20%) | 8 | (80%) | |
2/3 | 3 | (7.5%) | 0 | (0%) | 3 | (100%) | |
3/2 | 4 | (10%) | 4 | (100%) | 0 | (0%) | |
3/3 | 13 | (32.5%) | 0 | (0%) | 13 | (100%) | |
Cyclin D1 overexpression | |||||||
Negative | 23 | (57.5%) | 16 | (69.6%) | 7 | (30.4%) | < 0.001 |
Positive | 17 | (42.5%) | 0 | (0%) | 17 | (100%) | |
DJ1 overexpression | |||||||
Negative | 21 | (52.5%) | 16 | (76.2%) | 5 | (23.8%) | < 0.001 |
Positive | 19 | (47.5%) | 0 | (0%) | 19 | (100%) |
Gleason score | |||||||
= 7 | 2 | (8.3%) | 0 | (0%) | 2 | (100%) | 1.000 |
➢7 | 22 | (91.7%) | 7 | (31.8%) | 15 | (68.2%) | |
T | |||||||
T2 | 3 | (12.5%) | 1 | (33.3%) | 2 | (66.7%) | 1.000 |
T3 | 21 | (87.5%) | 6 | (28.6%) | 15 | (71.4%) | |
Stage | |||||||
Stage IIb | 3 | (12.5%) | 1 | (33.3%) | 2 | (66.7%) | 1.000 |
Stage III | 21 | (87.5%) | 6 | (28.6%) | 15 | (71.4%) | |
Cyclin D1 extent | |||||||
Positive | 24 | (100%) | 7 | (29.2%) | 17 | (70.8%) | --- |
DJ1 extent | |||||||
Positive | 24 | (100%) | 7 | (29.2%) | 17 | (70.8%) | --- |
Cyclin D1 extent /DJ1 extent | |||||||
+ve/+ve | 24 | (100%) | 7 | (29.2%) | 17 | (70.8%) | --- |
Cyclin D1 intensity | |||||||
2 | 11 | (45.8%) | 0 | (0%) | 11 | (100%) | 0.006 |
3 | 13 | (54.2%) | 7 | (53.8%) | 6 | (46.2%) | |
DJ1 intensity | |||||||
2 | 8 | (33.3%) | 0 | (0%) | 8 | (100%) | 0.054 |
3 | 16 | (66.7%) | 7 | (43.8%) | 9 | (56.3%) | |
Cyclin D1 intensity/DJ1 intensity | |||||||
2/2 | 8 | (33.3%) | 0 | (0%) | 8 | (100%) | 0.006§ |
2/3 | 3 | (12.5%) | 0 | (0%) | 3 | (100%) | |
3/3 | 13 | (54.2%) | 7 | (53.8%) | 6 | (46.2%) | |
Cyclin D1 overexpression | |||||||
Negative | 7 | (29.2%) | 7 | (100%) | 0 | (0%) | <0.001 |
Positive | 17 | (70.8%) | 0 | (0%) | 17 | (100%) | |
DJ1 overexpression | |||||||
Negative | 5 | (20.8%) | 5 | (100%) | 0 | (0%) | <0.001 |
Positive | 19 | (79.2%) | 2 | (10.5%) | 17 | (89.5%) |